Dermata Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRMA research report →
Range $6 – $6
Price Chart
About the company
Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis.
- CEO
- Gerald T. Proehl
- IPO
- 2021
- Employees
- 9
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on DRMA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $940.55K
- P/E
- -0.31
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 1.59
- EV/EBITDA
- 0.41
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -166.67%
- ROIC
- -246.61%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-7,773,598
- Net Income
- $-7,558,557+38.5%
- EPS
- $-8.16+89.8%
- OCF Growth
- -69393.8%
- FCF Growth
- -69393.8%
- 52W High
- $6.22
- 52W Low
- $0.95
- 50D MA
- $1.27
- 200D MA
- $1.70
- Beta
- 0.66
- RSI (14)
- 55
- Avg Volume
- 744.26K
No earnings-call transcripts are available for DRMA yet.
- Free Float
- 73.1%
- Shares Outstanding
- 681.56K
- Float Shares
- 498.53K
of shares held by institutions
7 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 16, 26 | PROEHL GERALD T | other | 1,360,544 |
| Aug 16, 26 | PROEHL GERALD T | other | 1,360,544 |
| Aug 16, 26 | PROEHL GERALD T | other | 1,360,544 |
| Aug 16, 26 | PROEHL GERALD T | other | 170,068 |
| Aug 16, 26 | PROEHL GERALD T | other | 170,068 |
| Aug 16, 26 | PROEHL GERALD T | other | 170,068 |
| Aug 16, 26 | Van Hoose Kyri K. | other | 102,040 |
| Aug 16, 26 | Van Hoose Kyri K. | other | 102,040 |
| Aug 16, 26 | Van Hoose Kyri K. | other | 102,040 |
| Jun 16, 26 | Scott Kathleen D. | sell | 11 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DRMA coverage
Recent articles, reports, and earnings notes.
No research on DRMA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DRMA report →Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
accessnewswire.com · Aug 17
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026
accessnewswire.com · Aug 11
Dermata Therapeutics Announces Commercial Launch Date for Tome(TM) Foundational Treatment
accessnewswire.com · Aug 5
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
accessnewswire.com · May 13
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
accessnewswire.com · Apr 2
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
accessnewswire.com · Mar 26
Head-To-Head Review: Pliant Therapeutics (NASDAQ:PLRX) versus Dermata Therapeutics (NASDAQ:DRMA)
defenseworld.net · Mar 21
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
accessnewswire.com · Mar 10
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.